Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

BACKGROUND: Patients with borderline resectable pancreatic cancer (BRPC) have poor prognosis with upfront surgery. METHODS: This was a single-arm Phase 2 trial for clinical and biomarker analysis. The primary endpoint is 1-year progression-free survival (PFS) rate. Patients received 8 cycles of neoa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoo, Changhoon, Lee, Sang Soo, Song, Ki Byung, Jeong, Jae Ho, Hyung, Jaewon, Park, Do Hyun, Song, Tae Jun, Seo, Dong Wan, Lee, Sung Koo, Kim, Myung-Hwan, Lee, Seung Soo, Kim, Jin Hee, Jin, Hyung-seung, Park, Jin-hong, Hwang, Dae Wook, Lee, Jae Hoon, Lee, Woohyung, Chang, Heung-Moon, Kim, Kyu-pyo, Ryoo, Baek-Yeol, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403346/
https://www.ncbi.nlm.nih.gov/pubmed/32433600
http://dx.doi.org/10.1038/s41416-020-0867-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403346/
https://www.ncbi.nlm.nih.gov/pubmed/32433600
http://dx.doi.org/10.1038/s41416-020-0867-x

Ejemplares similares